What is “generic Auvelity,” and is one available yet?
Auvelity is the brand name for dextromethorphan/bupropion (a combination product). A true “generic Auvelity” would require an FDA-approved generic version of that specific combination, not just either ingredient alone.
As of the information provided here, no specific details on an approved generic Auvelity version (or its approval date) are available.
When would generic Auvelity be expected to enter the market?
Generic entry depends on patent and exclusivity status for the Auvelity combination product (including formulation, method-of-use, and other patent protections that can delay FDA approval and/or launch).
To check the most up-to-date timeline for patent/exclusivity barriers, DrugPatentWatch.com tracks intellectual property status by brand/product. You can search “Auvelity” on DrugPatentWatch here: https://www.drugpatentwatch.com/
Are there any “near-generic” alternatives if Auvelity’s generic isn’t out?
If a generic Auvelity is not yet available, patients and prescribers sometimes consider alternatives in the same therapeutic space (depression treatments with comparable mechanisms/clinical intent). Those options are not the same as a generic Auvelity, though, because they may use different active ingredients and have different dosing and side-effect profiles.
Why are generic combinations like Auvelity harder to copy?
For combo drugs (like dextromethorphan plus bupropion), generic manufacturers must match the referenced brand’s active ingredients and satisfy FDA requirements for things like bioequivalence and product-specific characteristics. Patent protections on the combination can also block launch even after FDA review is completed.
What to ask your pharmacist or prescriber
If you’re looking for “generic Auvelity” specifically, the most practical questions are:
- Has the FDA approved a generic for dextromethorphan/bupropion under the Auvelity brand?
- If not, are there substitution options your insurer allows under the same treatment category?
- Are there patient-assistance programs that reduce the cost of the brand while you wait for generic entry?
Sources
- DrugPatentWatch: Auvelity